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The number of women who would need to be screened regularly by mammography to prevent one
death from breast cancer depends strongly on several factors, including the age at which regular
screening starts, the period over which it continues, and the duration of follow-up after screening.
Furthermore, more women would need to be INVITED for screening than would need to be
SCREENED to prevent one death, since not all women invited attend for screening or are screened
regularly. Failure to consider these important factors accounts for many of the major discrepancies
between different published estimates. The randomised evidence indicates that, in high income
countries, around one breast cancer death would be prevented in the long term for every 400
women aged 50–70 years regularly screened over a ten-year period.
R
andomized evidence has shown that regular mam-
mographic screening of women aged between
about 50 and 70 years reduces mortality from
breast cancer.
1–4 The absolute reduction in mortality
achieved by regular screening, and hence the number of
women who would need to be screened regularly over a
period of time to prevent one death from breast cancer,
depends on several factors. These include:
† women’s ages when screened, as incidence and
mortality rates for breast cancer increase with age;
† the period over which regular screening occurs;
† the duration of follow-up after a period of screening, as
deaths from the disease still occur two to three decades
after an initial diagnosis of breast cancer,
4,5 and treatment-
associated reductions in mortality from breast cancer con-
tinue into at least the second decade after the treatment;
6,7
† whether estimates relate to numbers of women who
would need to be invited for screening (which is what
randomized trials mostly address) or whether estimates
relate to the number who would need to accept an invi-
tation and be screened regularly (as not all women who
are invited for screening accept the invitation, or are
screened regularly);
† how often breast cancer would have been diagnosed inthe
absence of screening. This is changing over time, with
changes in the underlying incidence of the disease and
the increasing awareness of breast cancer, together with
the increasing need to investigate suspect breast
abnormalities.
Estimates in the table are all derived from randomized trial
results. Section A gives the estimated numbers who would
need to be INVITED for screening to prevent one death
from breast cancer.
2,3 The US Preventive Services Task
Force
2 subdivided their estimates by women’s ages at ﬁrst
invitation. As expected, the estimated numbers that would
need to be invited for screening to prevent one death from
breast cancer is substantially greater for younger than for
older women – for example, they estimate that approxi-
mately ﬁve times as many women aged 40–49 than 60–
69 years would need to be invited for screening to prevent
one death from breast cancer (1904 vs 377, see Table 1).
These estimates are based on breast cancer deaths occurring
during the ﬁrst 13 or so years after women were ﬁrst invited
for screening.
Gotzsche and Nielsen
3 state ‘for every 2000 women
invited for screening throughout 10 years, one will have
her life prolonged’. However, the authors do not state the
age group to which their estimate applies, and it is unclear
whether ‘throughout 10 years’ refers to the period of invita-
tion, the period of follow-up, or both.
Section B of the table gives the estimated numbers needed
to SCREEN to prevent one death from breast cancer.
4,5
Recent data published by Tabar et al.
4 from two randomized
trials in Sweden (the ‘Two County’ trial) illustrate the
importance of duration of follow-up, as fewer than half
the deaths from breast cancers diagnosed during the screen-
ing period occurred in the ﬁrst 10 years of follow-up after
ﬁrst randomization. They estimate that, after 29 years of
follow-up for women aged 40–74 years at ﬁrst screen, 519
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approximately 400 such women would need to be screened
over a 10-year period, to prevent one death from breast
cancer.
4
Only 85% of those invited for screening in the Swedish
Two County trial accepted any single invitation and fewer
still were screened regularly.
4 Furthermore, some women in
the control arm of the trial were screened (outside the trial)
during the study period. Because randomized trials generally
assess the reduction in mortality associated with being invited
for screening, it follows that results from such trials do not
provide a direct measure of the reduction in mortality associ-
ated with being screened. Trial results for women invited for
screening are inevitably diluted by the misclassiﬁcation of
women’s true screening history, both in the intervention
arm and in the control arm. The International Agency for
Research on Cancer
1 used randomized trial results to estimate
the relative risk for breast cancer mortality associated both
with being invited for screening and with being screened,
adjusting for the measurement error associated with misclas-
sifying women in the trials. As would be expected, they found
a greater relative reduction in breast cancer mortality associ-
ated with being screened than with being invited for screen-
ing.
1 (As would also be expected, the International Agency
for Research on Cancer
1 and the US Preventive Services
Task Force
2 found similar relative risks for breast cancer mor-
tality among women aged 50–69 years who were INVITED
for screening, as the same trials were included in the analyses
for both reports.)
The Advisory Committee on Breast Cancer Screening
(ACBCS)
5 estimated that 400 women in England aged 50–
70 years would need to be screened regularly over a
10-year period to prevent one death from breast cancer
during the 30 or so years after women’s ﬁrst screen
(i.e. including the 20 or so years after women’s last
screen). The ACBCS’s estimate was calculated by applying
relative risks for screened women, derived by the
International Agency for Research on Cancer,
1 to breast
cancer deaths in England in 2003. Although the methods
used by the ACBCS
5 were different to those used by Tabar
et al.,
4 the estimate that 400 women aged 50–70 in
England would need to be screened regularly over 10
years to prevent one death from breast cancer is the same
as that made by Tabar et al. that 400 women aged 40–74
years in Sweden would need to be screened over a 10-year
period to prevent one death from breast cancer.
Furthermore, only about three-quarters of the women in
England who are invited for screening accept the invitation,
5
and so the US Preventive Services Task Force’s estimates of
the numbers aged 50–69 years who would need to be
invited for screening are broadly consistent with the ACBCS
estimates for the number of women who would need to be
screened, after allowing for the incomplete uptake of screen-
ing by those invited and differences in the duration of follow-
up.
When inviting women for screening, as the NHS Breast
Screening Programme does, it is appropriate to provide stat-
istics on numbers needed to SCREEN to prevent one breast
cancer death. (If the number needed to invite for screening
were quoted, it might be taken to imply that the invitation
itself was sufﬁcient to prevent death from breast cancer.)
Also, estimates of the number needed to screen to prevent
one death from breast cancer needs to reﬂect the long-
term effect of screening, not just what happens in the ﬁrst
decade or so after an initial screen (as screening in a given
10-year period prevents more deaths after that 10-year
period ends than during it).
In summary, based on randomized evidence, it is reason-
able to conclude that, in high income countries, around one
breast cancer death would be prevented in the long term for
every 400 women aged 50–70 years regularly screened over
a ten-year period. The numbers needed to screen to prevent
one death from breast cancer depend strongly on the age at
which regular screening starts, the period over which it con-
tinues, and the duration of follow-up after screening. Failure
to consider these important inﬂuences on breast cancer mor-
tality accounts for many of the major discrepancies between
different published estimates.
Table 1 Estimated numbers of women that would need to be (A) invited for screening and (B) screened to prevent one death from
breast cancer
Published reference
Age at: (A) ﬁrst
invitation, (B) ﬁrst
screen
Period of (A) invitation
or (B) screening
Follow-up after: (A) ﬁrst
invitation, (B) ﬁrst screen
Estimated absolute numbers (A) to invite
or (B) to screen, to prevent one death
from breast cancer (& 95% CI)
A. Numbers needed to INVITE for screening to prevent one breast cancer death
US Preventive
Services Task
Force
2
40–49 years 7 years 13 years 1904 (929–6378)
50–59 years 7 years 13 years 1339 (322–7455)
60–69 years 7 years 13 years 377 (230–1050)
Gotzsche &
Nielsen
3
not stated
† unclear
† unclear
† 2000 (CI not stated)
B. Numbers needed to SCREEN to prevent one breast cancer death
Tabar et al
4‡ 40–74 years 7 years 10 years 1303 (621–13169)
20 years 577 (370–1315)
29 years 519 (336–1144)
ACBCS
5 50–70 years 10 years .30 years 400 (CI not stated)
The average time between each INVITATION for screening in the 8 trials reviewed by the US Preventive Services Task Force
2 ranged from 12 months to 21
2 years. The average time between each
SCREEN in the Swedish Two County trial
4 was 33 months, and the time between each screen assumed to be 36 months by the Advisory Committee on Breast Cancer Screening (ACBCS)
5
†It is unclear whether Gotzsche and Nielsen’s estimate is for invitations over a 10-year period or for follow-up over 10 years or both (see text); and the age group to which their estimate applies is
not stated, but may have been heavily weighted by women aged under 50 years
3
‡Based on breast cancer deaths assessed by the Swedish Overview Consensus Committee
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